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IN VIVO MEASUREMENT OF TRANSLATIONAL AND 
ROTATIONAL LAXITY OF RABBIT KNEES 
AD Heine[, MJ Rudert, TO McKinley, DC Fredericks, JA Bobst, Y 
Tochigi 
Orthopaedics and Rehabilitation, University of Iowa, Iowa City, IA 
Aim of Study: The aim of this study was to design and evaluate 
a device to measure rabbit knee joint laxity as a function of partial 
and full ACL sectioning, as a way to explore the pathomechanics 
of osteoarthritis. 
Methods: The testing device for measuring rabbit knee joint lax- 
ity consists of a main cradle with an integral femur clamp, a 
free-floating tibia clamp, and interchangeable linear stepper mo- 
tor/load cell modules - one for translational and one for rotational 
testing (Fig. 1). The rotational test module incorporates a rack- 
and-pinion linkage to convert linear to rotary motion. Both mod- 
ules include a method to adjust knee flexion angle to 90 or 135 
degrees. Test control and data acquisition are by user-written 
LabView programs running on a laptop computer. 
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Fig. 1. Rabbit knee testing system, translational (left) and rotational (right) 
modules. 
To prepare a rabbit for testing, coronal plane transverse pins are 
inserted through the rabbit leg, two in the tibia and one in the 
distal femur. The pins are accurately placed using a drill guide, 
and serve to reproducibly position the leg in the test device for 
repeated testing. During testing, the rabbit is on its back and the 
femur is held fixed vertically. The translational module draws the 
tibia upward for a specified distance and speed, then returns to 
the home position. The rotational module rotates the tibia in one 
direction and then the other, then returns to the home position; 
test angles and speed are user-specified. Force-displacement or 
torque-angle data are displayed and saved to a file. 
We evaluated the effects of preconditioning, intra-operator e- 
peatability (by removing and replacing the rabbit in the fixture), 
knee flexion angle, and ACL sectioning. 
Results: Three to four preconditioning cycles were sufficient to 
get repeatable cycle-to-cycle results. Removing and replacing the 
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Fig. 2. Rabbit knee stiffness with drawer test, intact vs. sectioned and 90 vs. 
135 degrees knee flexion. 
Table 1. Repeatability ofrabbit knee stiffness when rabbit is removed from 
the fixture and replaced (n=3) 
Knee angle Drawer test Rotation test 
90 ° 5.2% 6.9% 
135 ° 1.6% 4.4% 
rabbit from the fixture had little effect on the testing results (Table 
1). The testing device can measure the difference in stiffness of 
a rabbit knee when the knee is at 90 vs. 135 degrees, and when 
the ACL is intact vs. sectioned (Fig. 2). 
Conclusions: This device can be used to determine rabbit knee 
laxity in vivo. 
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QUANTIFICATION OF AGGRECAN FRAGMENTS IN 
SYNOVIAL FLUID IN HUMAN OSTEOARTHRITIS 
SH Larsson 1 , A Struglics 1 , MA Pratta 2, S Kumar 2, MW Lark 3, 
LS Lohmander 1 
1Department of Orthopaedics, Clinical Sciences Lund, Lund 
University, Lund, Sweden; 2Musculoskeletal Diseases Biology, 
GlaxoSmithKline, Collegeville, PA; 3Centocor Inc., Malvern, PA 
Aim of study: Quantification of aggrecanase generated 
374ARGS and matrix metalloproteinase (MMP) generated 
342 FFGV neoepitope aggrecan fragments in human osteoarthritis 
(OA) synovial fluid. 
Introduction: Although most current reports suggest that a ma- 
jority of the destructive aggrecanolysis in human OA is due to ag- 
grecanase activity in the interglobular domain (IG D), other studies 
suggest that variable but quantitatively not well determined pro- 
portions of the IGD cleavage may be due to activity of MMP's. A 
quantitative and specific assay to monitor degradation of aggre- 
can is an important ool in the development of disease modifying 
therapies in OA, but has proven challenging to develop. We have 
in Western immunoblots quantified the aggrecanase generated 
374ARGS and MMP generated 342FFGV neoepitope fragments in 
a pool of human OA synovial fluid. 
Methods: Human synovial fluid aggrecan was purified from 
pooled synovial fluids from 47 OA patients by dissociative CsCI 
centrifugation, collecting the D1 fraction; proteinase inhibitors be- 
ing present in all steps. As quantification standards, aggrecan 
(A1D1 fraction) from adult human articular cartilage was com- 
pletely converted to either 374ARGS or 342FFGV fragments (with 
corresponding G1-TEGE 373 and GI-IPEN 341 fragments) by di- 
gestion with MMP-3 or with ADAMTS-4. The standards were as- 
sumed to contain one nmol 342FFGV or 374ARGS fragments per 
mg aggrecan dry weight, using a molecular weight of 1 xl  06 g/mol 
aggrecan. Prior to SDS-PAGE and immunoblotting all samples 
were deglycosylated with chondroitinase ABC, keratanase and 
keratanase II. Aggrecan neoepitope antibodies recognizing the 
374ARGS and 342FFGV neoepitope sequences were used. The 
detection and quantification was conducted in a luminescence 
image analyzer (Fujifilm LAS-1000) using Image Gauge version 
4.0 (Fujifilm) software. Samples and standards were used within 
a linear range of the imaging system. 
Results: The content in pooled synovial fluid of large size aggre- 
can fragments with N-terminals374ARGS and 342FFGV was 107 
and 40 pmoles per ml, respectively, out of a total concentration 
of aggrecan fragments of about 185 pmoles per ml. The resulting 
mol/mol ratio of 374ARGS over 342FFGV was 2.7 in this pool of 
human OA synovial fluids. 
Conclusions: We have in Western immunoblots, using neoepi- 
tope antibodies, quantified aggrecanase generated 374ARGS and 
MMP generated 342FFGV neoepitope aggrecan fragments in a 
pool of human OA synovial fluid. Monitoring the relative contents 
of these fragments in individual patient samples over time might 
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prove important in revealing the roles of aggrecanase versus 
MMP aggrecanolysis in the IGD of aggrecan at different stages 
of human OA. 
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INCREASED SYNOVIAL FLUID AND DECREASED 
SERUM BONE ALKALINE PHOSPHATASE 
CONCENTRATIONS ASSOCIATED WITH EQUINE 
OSTEOCHONDRAL FRAGMENTATION 
TN Trumble, MP Brown, KA Merritt 
Large Animal Clinical Sciences, University of Florida, 
Gainesville, FL 
Aim of study: To determine the bone alkaline phosphatase 
(BAP) concentrations in the synovial fluid and serum from horses 
with osteochondral fragmentation compared to normal, treadmill- 
exercised horses. 
Methods: Synovial fluid was collected from the carpal joints and 
blood was collected from the jugular vein of 9 mature Thorough- 
bred horses presented for arthroscopic debridement of osteo- 
chondral fragmentation. As a comparable xercise control group, 
serum and carpal synovial fluid samples were collected from 
14 mature Thoroughbred horses after 6 weeks of regular tread- 
mill training. BAP concentrations were measured in the synovial 
fluid and serum using a commercially available immunoassay 
(Metra TM BAP, Quidel Corporation, San Diego, CA). Synovial fluid 
and serum were compared between the osteochondral fragment 
group of horses and the exercise control group using an unpaired 
t-test. A value of P<0.05 was considered significant. 
Results: The synovial fluid BAP concentration was significantly 
elevated (P<0.01) in the horses with osteochondral fragments 
(mean 4- standard deviation, 21.87 4- 8.4 U) compared to the ex- 
ercise control horses (13.32 4- 6.44 U). However, the serum BAP 
concentration was significantly lower (P<0.001) in the horses 
with osteochondral fragments (31.45 4- 8.44 U) compared to the 
exercise control horses (52.33 4- 11.64 U). 
Conclusions: The elevated concentrations of BAP in the syn- 
ovial fluid of horses with osteochondral fragments compared to 
exercise control horses may be due to local production and re- 
lease of the enzyme from the exposed subchondral bone and 
inflamed synovium. In addition, delayed clearance of BAP from 
the joint as a result of joint effusion may also result in greater 
synovial fluid concentrations. The lower concentrations of BAP in 
the serum of horses with osteochondral fragmentation compared 
to exercise control horses may be due to the basic physiologic re- 
sponse of bone to exercise compared to injury. In the uninjured, 
exercised horse, bone formation (modeling) predominates to ad- 
just to the loads applied during exercise. However, when acute in- 
jury to the bone occurs, as with osteochondral fragmentation, the 
bone may go through a remodeling process. If so, the bone must 
first go through a resorptive period before the osteoblasts would 
be recruited to the site to initiate new bone formation. Therefore, 
due to this relatively delayed response of the osteoblasts, the 
serum BAP concentrations may be lower in the osteochondral 
fragmentation horses compared to horses with exercise-induced 
modeling. Examination of both the synovial fluid and serum BAP 
concentrations in various types of joint disease is valuable in de- 
termining the different local and systemic effects that occur in re- 
sponse to the joint disease. 
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EVALUATION OF AGGRECAN FRAGMENTS BY USING 
TWO COLOR INFRARED IMAGING DETECTION 
S Yao 1 , X Qu 1 , QL Carter 1 , MG Chambers 2, KC Cox 1 , 
K Duffin 1,2, J Dotzlaf 1 , TE Eessalu 1 , PG Mitchell 2, 
CA Swearingen 2, K Thirunavukkarasu 2,A Harvey 2, 
S Chandrasekhar 2, R Yao 1 
1Lilly Greenfield Laboratories, Eli Lilly & Company, Greenfield, 
IN; 2Lilly Research Laboratories, Eli Lilly & Company, 
Indianapolis, IN 
The ability to quantitate aggrecan fragments and their neoepi- 
topes in both plasma and synovial fluids is important for the devel- 
opment of biomarkers that will monitor aggrecan degradation in 
osteoarthritis. While the ultimate goal of these biomarker efforts is 
the development of high sensitivity, reproducible assays capable 
of evaluating large number of clinical and preclinical samples, it is 
essential that these results can be independently validated using 
different echnology to insure the specificity of the immunoassays 
under development. Accordingly, the present study has focused 
on the detection of aggrecan fragments by Western blot analysis 
using two color infrared imaging technology. Initial studies have 
focused on the detection of a 32 amino acid peptide fragment (32- 
mer) following aggrecan digestion with matrix metalloprotease 13 
and ADAMTS 4/5. A rabbit affinity purified polyclonal with recog- 
nition of the carboxy terminus and a mouse monoclonal recogniz- 
ing the amino terminus of the peptide were used to detect the 32- 
mer by Western blot analysis following SDS gel electrophoresis 
of the aggrecan digests. The fluorochrome conjugated detection 
antibodies (anti rabbit and anti mouse) were chosen based on the 
780 and 680 excitation wavelengths of the Odyssey's two diode 
lasers. This technology insures the specificity of the antibodies 
used for higher throughput assays by requiring co-staining with 
both antibodies to the aggrecan peptide of interest and is eas- 
ily visualized in the same sample lane. The ability to utilize this 
approach in complex biologic matrices will provide a greater un- 
derstanding of both neoepitope levels as well as the potential size 
diversity of the neoepitope containing aggrecan fragments in both 
clinical and preclinical samples. 
P79 
DEVELOPMENT OF COMPETITIVE ELISAS FOR THE 
DETECTION OF AGGRECANASE CLEAVED FRAGMENTS 
OF AGGRECAN 
QL Carte(, M Chambers, K Cox, J Dotlaz, K Duffin, T Eessalu, P 
Mitchell, C Swearingen, K Thirunavukkarasu, R Yao 
Greenfield Laboratories, Eli Lilly and Company, Greenfield, IN; 
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, 
IN 
The cleavage of aggrecan by aggrecanases (e.g. ADAMTS-4/5) 
generates a series of neoepitope xposed fragments which are 
thought to be potential candidates for Osteoarthritis (OA) asso- 
ciated biomarkers. The ability to detect these neoepitope frag- 
ments in patient samples could potentially aid physicians and re- 
searchers in providing additional criteria in conjunction with clin- 
ical signs for selecting the most appropriate and effective treat- 
ments for symptom amelioration or disease modification. In the 
present study, a series of competitive nzyme-linked immunoab- 
sorbent assays (ELISAs) have been developed to quantitate OA 
biological samples for the most abundant neoepitope fragments 
using affinity purified rabbit polyclonal antibodies (poABs) de- 
rived following synthetic peptide immunizations. These antibod- 
ies were characterized by BIACORE analysis with KD values for 
the specific neoepitope sequences between 10-1° to 10-8M. In 
the competitive ELISA format, the assay measures the ability of 
